Upload
Featured Recent Articles Topics Login Upload

Search Results for 'clinical biosimilars'

clinical biosimilars published presentations and documents on DocSlides.

Application of Biosimilars in RA IN Clinical Practice:
Application of Biosimilars in RA IN Clinical Practice:
by conchita-marotz
Key Issues and Challenges.  . Introduction. Diff...
Biosimilars in emerging markets- regulatory and Commercial considerations
Biosimilars in emerging markets- regulatory and Commercial considerations
by jane-oiler
OMIC Group. Biosimilars 2104. Hyderabad. India. 2...
Biosimilars
Biosimilars
by lindy-dunigan
Knowledge Connect Slide Resource. This slide dec...
  What is the value of Real-World Evidence for Biosimilars?
  What is the value of Real-World Evidence for Biosimilars?
by bitsy
Disclaimer. This panel is moderated by Dr. Delphin...
Biosimilars & EU regulation
Biosimilars & EU regulation
by karlyn-bohler
Alice DOMINIQUE - M2 AREIPS. 1. Content. 2. Defin...
Biosimilars in RA: A Blessing or a Curse?
Biosimilars in RA: A Blessing or a Curse?
by conchita-marotz
Introduction/Overview . What Is a Biosimilar?. Di...
1 Immunogenicity The key safety issue for biosimilars
1 Immunogenicity The key safety issue for biosimilars
by gelbero
Prof. Ibrahim A. . Alsarra. Professor . of . Phar...
PhAMA Position on Biosimilar Medicines
PhAMA Position on Biosimilar Medicines
by celsa-spraggs
Ms. Leah Goodman. Contents. Key Messages. An Over...
Biological Products: concepts, naming,
Biological Products: concepts, naming,
by faustina-dinatale
interchangeability,extrapolation. and safety. Dr...
Challenges in demonstrating biosimilarity and interchangeability of biosimilar products
Challenges in demonstrating biosimilarity and interchangeability of biosimilar products
by calandra-battersby
OMICS Group Biosimilars 2015 Birmingham, UK. 10-1...
Category 1: Defining Terms
Category 1: Defining Terms
by jasmine
Clue: . A biologic product with no clinically mean...
Acceptable changes in quality attributes of glycosylated bi
Acceptable changes in quality attributes of glycosylated bi
by debby-jeon
Schiestl M, Stangler T, Torella C, et al. . Nat B...
Understanding Biologics Biologics and Biosimilars
Understanding Biologics Biologics and Biosimilars
by calandra-battersby
Animation: What Are Biologics?. Production of Bio...
Comparison of US/EU Biosimilar
Comparison of US/EU Biosimilar
by aaron
Guidelines. Kamali Chance, MPH, PhD, RAC. Senior...
Comparison of US/EU Biosimilar
Comparison of US/EU Biosimilar
by myesha-ticknor
Guidelines. Kamali Chance, MPH, PhD, RAC. Senior...
Biosimilars Guideline – a Summary of the Industry Comments
Biosimilars Guideline – a Summary of the Industry Comments
by marina-yarberry
M Bredenhann | Nycomed | 19.11.10. BIOSIMILAR...
Comparison of US/EU Biosimilar
Comparison of US/EU Biosimilar
by danika-pritchard
Guidelines. Kamali Chance, MPH, PhD, RAC. Senior...
Faculty Leonard H. Calabrese, DO
Faculty Leonard H. Calabrese, DO
by trish-goza
Professor of Medicine. Cleveland Clinic Lerner Co...
Challenges in demonstrating biosimilarity and interchangeability of biosimilar products
Challenges in demonstrating biosimilarity and interchangeability of biosimilar products
by stefany-barnette
OMIC Group Biosimilars 2014. Hyderabad India. 27-...
Biosimilars and biologics –
Biosimilars and biologics –
by gelbero
What does personalisation . mean . for you?. Ian N...